²²⁵Aс-PSMA-617 therapy in metastatic castration-resistant prostate cancer

177Lu-PSMA-617 is a new therapy option for PSMA-positive metastatic castrate-resistant metastatic prostate cancer (mCRPC) with proven efficacy. 225Ac-PCMA-617 is an alpha emitter, making this drug potentially more powerful. Despite the active use of 225Ac-PSMA-617 worldwide, no randomized phase III...

Fuld beskrivelse

Bibliografiske detaljer

Principais autores:	T. Yu. Kochetova, V. V. Krylov, S. A. Ivanov, A. D. Kaprin
Format:	Artigo
Sprog:	Russo
Udgivet:	Russian Academy of Sciences, Tomsk National Research Medical Center 2025-01-01
Serier:	Сибирский онкологический журнал
Fag:	radioligand therapy <sup>225</sup>ac-psma-617 castrate-resistant prostate cancer radium chloride [<sup>223</sup>ra] overall survival
Online adgang:	https://www.siboncoj.ru/jour/article/view/3360
Tags:	Tilføj Tag Ingen Tags, Vær først til at tagge denne postø!